Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
نویسندگان
چکیده
According to the 2016 National Comprehensive Cancer Network (NCCN) guidelines, patients with borderline resectable pancreatic cancer (BRPC) should receive chemotherapy as first-line treatment. This study examined real-world survival benefits of modifying BRPC treatment guidelines. Patients treated for at a single institution from 2013 2015 (pre-guideline group) and 2017 2019 (post-guideline were retrospectively reviewed. method used, classified into upfront surgery (US), after neoadjuvant (NAT), only (CO) groups. Overall (OS) was compared according period type. Factors associated OS analyzed using Cox regression model. Among 165 patients, 63 in pre-guideline group 102 post-guideline group. The median significantly improved (29 vs. 13 months, p < 0.001). method, NAT longer than that US CO groups (40 16 15 respectively, In multivariate analysis, tumor size, differentiation, NAT, perineural invasion significant prognostic factors. is an important option increased patient real world.
منابع مشابه
Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL-PDAC) is increasing. However, the impact of neoadjuvant chemotherapy and radiation therapy on the outcome of BL-PDAC remains to be elucidated. We performed a retrospective analysis of 93 consecutive patients who were diagnosed with BL-PDAC and primarily followed at Johns Hopkins Hospital bet...
متن کاملNeoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer
The majority of patients with localized pancreatic cancer (PC) who undergo surgery followed by adjuvant therapy will develop metastatic disease, suggesting that surgery alone is not sufficient for cure and micrometastases are present even when are not clinically detected. As such, the delivery of early systemic therapy may be a rational alternative to a surgery-first approach, in an effort to p...
متن کاملSurvival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
Purpose Neoadjuvant treatment may provide improved survival outcomes for patients with borderline resectable pancreatic cancer (BRPC). The purpose of this study is to evaluate the clinical outcomes of neoadjuvant treatment and to identify prognostic factors. Methods Forty patients who met the National Comprehensive Cancer Network definition of BRPC and received neoadjuvant treatment followed ...
متن کاملBorderline resectable pancreatic cancer.
Rigorous criteria to define "borderline resectable" pancreatic cancer are required for appropriate patient accrual into clinical trials that examine the utility of chemotherapy and/or chemoradiation that will be delivered prior to pancreatic resection for exocrine cancer. At our institution, tumor abutment of less than or equal to 180 degrees (< or = 50% of the vessel circumference) of the supe...
متن کاملPreoperative Biliary Drainage in Cases of Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgery
Objective. To elucidate the optimum preoperative biliary drainage method for patients with pancreatic cancer treated with neoadjuvant chemotherapy (NAC). Material and Methods. From January 2010 through December 2014, 20 patients with borderline resectable pancreatic cancer underwent preoperative biliary drainage and NAC with a plastic or metallic stent and received NAC at Hiroshima University H...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biomedicines
سال: 2023
ISSN: ['2227-9059']
DOI: https://doi.org/10.3390/biomedicines11082302